These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 37646663)

  • 1. MYC protein is a high-risk factor in mantle cell lymphoma and identifies cases beyond morphology, proliferation and
    Rodrigues JM; Hollander P; Schmidt L; Gkika E; Razmara M; Kumar D; Geisler C; Grønbæk K; Eskelund CW; Räty R; Kolstad A; Sundström C; Glimelius I; Porwit A; Jerkeman M; Ek S
    Haematologica; 2024 Apr; 109(4):1171-1183. PubMed ID: 37646663
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MYC overexpression correlates with MYC amplification or translocation, and is associated with poor prognosis in mantle cell lymphoma.
    Choe JY; Yun JY; Na HY; Huh J; Shin SJ; Kim HJ; Paik JH; Kim YA; Nam SJ; Jeon YK; Park G; Kim JE
    Histopathology; 2016 Feb; 68(3):442-9. PubMed ID: 26100211
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic significance of p53, Sox11, and Pax5 co-expression in mantle cell lymphoma.
    Jing C; Zheng Y; Feng Y; Cao X; Xu C
    Sci Rep; 2021 Jun; 11(1):11896. PubMed ID: 34099776
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High incidence of MYC and BCL2 abnormalities in mantle cell lymphoma, although only MYC abnormality predicts poor survival.
    Yi S; Zou D; Li C; Zhong S; Chen W; Li Z; Xiong W; Liu W; Liu E; Cui R; Ru K; Zhang P; Xu Y; An G; Lv R; Qi J; Wang J; Cheng T; Qiu L
    Oncotarget; 2015 Dec; 6(39):42362-71. PubMed ID: 26517511
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of cyclin D1 mRNA isoforms, morphology and p53 in mantle cell lymphoma: p53 alterations and blastoid morphology are strong predictors of a high proliferation index.
    Slotta-Huspenina J; Koch I; de Leval L; Keller G; Klier M; Bink K; Kremer M; Raffeld M; Fend F; Quintanilla-Martinez L
    Haematologica; 2012 Sep; 97(9):1422-30. PubMed ID: 22315488
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aggressive B-cell Lymphoma with MYC/TP53 Dual Alterations Displays Distinct Clinicopathobiological Features and Response to Novel Targeted Agents.
    Deng M; Xu-Monette ZY; Pham LV; Wang X; Tzankov A; Fang X; Zhu F; Visco C; Bhagat G; Dybkaer K; Chiu A; Tam W; Zu Y; Hsi ED; You H; Huh J; Ponzoni M; Ferreri AJM; Møller MB; Parsons BM; Hagemeister F; van Krieken JH; Piris MA; Winter JN; Li Y; Xu B; Liu P; Young KH
    Mol Cancer Res; 2021 Feb; 19(2):249-260. PubMed ID: 33154093
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Eskelund CW; Dahl C; Hansen JW; Westman M; Kolstad A; Pedersen LB; Montano-Almendras CP; Husby S; Freiburghaus C; Ek S; Pedersen A; Niemann C; Räty R; Brown P; Geisler CH; Andersen MK; Guldberg P; Jerkeman M; Grønbæk K
    Blood; 2017 Oct; 130(17):1903-1910. PubMed ID: 28819011
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mantle Cell Lymphoma With MYC Rearrangement: A Report of 17 Patients.
    Hu Z; Medeiros LJ; Chen Z; Chen W; Li S; Konoplev SN; Lu X; Pham LV; Young KH; Wang W; Hu S
    Am J Surg Pathol; 2017 Feb; 41(2):216-224. PubMed ID: 27776009
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mantle cell lymphomas with concomitant MYC and CCND1 breakpoints are recurrently TdT positive and frequently show high-grade pathological and genetic features.
    Aukema SM; Croci GA; Bens S; Oehl-Huber K; Wagener R; Ott G; Rosenwald A; Kluin PM; van den Berg E; Bosga-Bouwer AG; Hoogendoorn M; Hoster E; Bittmann I; Nagel I; Murga Penas EM; Kreuz M; Bausinger J; Belder W; Oschlies I; Dyer MJS; Jayne S; Siebert R; Klapper W
    Virchows Arch; 2021 Jul; 479(1):133-145. PubMed ID: 33528622
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutant mice lacking alternatively spliced p53 isoforms unveil
    Fajac A; Simeonova I; Leemput J; Gabriel M; Morin A; Lejour V; Hamon A; Rakotopare J; Vaysse-Zinkhöfer W; Eldawra E; Pinskaya M; Morillon A; Bourdon JC; Bardot B; Toledo F
    Elife; 2024 Sep; 13():. PubMed ID: 39298333
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of genetic changes in MCL by interphase FISH on tissue sections.
    Sander B; Wallblom A; Ekroth A; Porwit A; Kimby E
    Leuk Lymphoma; 2007 Jul; 48(7):1344-52. PubMed ID: 17613764
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of Single or Combined Genomic Alterations of TP53, MYC, and BCL2 on Survival of Patients With Diffuse Large B-Cell Lymphomas: A Retrospective Cohort Study.
    Schiefer AI; Kornauth C; Simonitsch-Klupp I; Skrabs C; Masel EK; Streubel B; Vanura K; Walter K; Migschitz B; Stoiber D; Sexl V; Raderer M; Chott A; da Silva MG; Cabecadas J; Müllauer L; Jäger U; Porpaczy E
    Medicine (Baltimore); 2015 Dec; 94(52):e2388. PubMed ID: 26717387
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Wang L; Tang G; Medeiros LJ; Xu J; Huang W; Yin CC; Wang M; Jain P; Lin P; Li S
    Haematologica; 2021 May; 106(5):1381-1389. PubMed ID: 32273477
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-Hodgkin's lymphomas with Burkitt-like cells are associated with c-Myc amplification and poor prognosis.
    Mossafa H; Damotte D; Jenabian A; Delarue R; Vincenneau A; Amouroux I; Jeandel R; Khoury E; Martelli JM; Samson T; Tapia S; Flandrin G; Troussard X
    Leuk Lymphoma; 2006 Sep; 47(9):1885-93. PubMed ID: 17065002
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolic reprogramming in triple-negative breast cancer through Myc suppression of TXNIP.
    Shen L; O'Shea JM; Kaadige MR; Cunha S; Wilde BR; Cohen AL; Welm AL; Ayer DE
    Proc Natl Acad Sci U S A; 2015 Apr; 112(17):5425-30. PubMed ID: 25870263
    [TBL] [Abstract][Full Text] [Related]  

  • 16. p53 and mdm2 in mantle cell lymphoma in leukemic phase.
    Solenthaler M; Matutes E; Brito-Babapulle V; Morilla R; Catovsky D
    Haematologica; 2002 Nov; 87(11):1141-50. PubMed ID: 12414343
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD5-negative blastoid variant mantle cell lymphoma with complex CCND1/IGH and MYC aberrations.
    Seok Y; Kim J; Choi JR; Kim YR; Park SJ; Kim SJ; Song J; Lee KA
    Ann Lab Med; 2012 Jan; 32(1):95-8. PubMed ID: 22259787
    [TBL] [Abstract][Full Text] [Related]  

  • 18. p53 expression in large B-cell lymphomas with MYC extra copies and CD99 expression in large B-cell lymphomas in relation to MYC status.
    Richardson AI; Zhang D; Woodroof J; Cui W
    Hum Pathol; 2019 Apr; 86():21-31. PubMed ID: 30496802
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Whole genome copy number analysis in search of new prognostic biomarkers in first line treatment of mantle cell lymphoma. A study by the LYSA group.
    Le Bris Y; Magrangeas F; Moreau A; Chiron D; Guérin-Charbonnel C; Theisen O; Pichon O; Canioni D; Burroni B; Maisonneuve H; Thieblemont C; Oberic L; Gyan E; Pellat-Deceunynck C; Hermine O; Delfau-Larue MH; Tessoulin B; Béné MC; Minvielle S; Le Gouill S
    Hematol Oncol; 2020 Oct; 38(4):446-455. PubMed ID: 32472610
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of TP53 is associated with the outcome of MCL independent of MIPI and Ki-67 in trials of the European MCL Network.
    Aukema SM; Hoster E; Rosenwald A; Canoni D; Delfau-Larue MH; Rymkiewicz G; Thorns C; Hartmann S; Kluin-Nelemans H; Hermine O; Dreyling M; Klapper W
    Blood; 2018 Jan; 131(4):417-420. PubMed ID: 29196411
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.